Jasper Therapeutics announces follow-up data from briquilimab study for SCD

Jasper Therapeutics announced that additional follow-up data from Jasper’s investigator-sponsored study of briquilimab as a conditioning agent in the treatment of sickle cell disease SCD were presented in a plenary session focused on novel antibody-based conditioning regimens at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR. Dr. John F. Tisdale, Director of the Cellular and Molecular Therapeutics Laboratory, National Heart, Lung, and Blood Institute, delivered the talk, titled "Improving the Landscape for Curative Therapies in Sickle Cell Disease with Novel Conditioning Methods." The study is a Phase 1/2 clinical trial ,NCT05357482, evaluating the addition of briquilimab, Jasper’s anti-c-Kit monoclonal antibody, to an existing bone marrow transplantation regimen in individuals with SCD and beta thalassemia considered at high risk for complications from or ineligible for standard myeloablative hematopoietic stem cell transplant. The addition of briquilimab is being studied as a potential way to achieve a higher percentage of healthy donor stem cell engraftmen without increased toxicity. Initial data from this study were previously shared by Jasper via press release on January 3.